Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 28;15(5):1076.
doi: 10.3390/v15051076.

Impact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients

Cathrin Kodde  1   2 , Finja Timmen  3 , Sven Hohenstein  4 , Andreas Bollmann  4 , Marzia Bonsignore  5   6 , Ralf Kuhlen  7 , Irit Nachtigall  8   9 , Selcuk Tasci  10
Affiliations

Impact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients

Cathrin Kodde et al. Viruses. .

Abstract

Background: Even though several therapeutic options are available, COVID-19 is still lacking a specific treatment regimen. One potential option is dexamethasone, which has been established since the early beginnings of the pandemic. The aim of this study was to determine its effects on the microbiological findings in critically ill COVID-19 patients.

Methods: A multi-center, retrospective study was conducted, in which all the adult patients who had a laboratory-confirmed (PCR) SARS-CoV-2 infection and were treated on intensive care units in one of twenty hospitals of the German Helios network between February 2020-March 2021 were included. Two cohorts were formed: patients who received dexamethasone and those who did not, followed by two subgroups according to the application of oxygen: invasive vs. non-invasive.

Results: The study population consisted of 1.776 patients, 1070 of whom received dexamethasone, and 517 (48.3%) patients with dexamethasone were mechanically ventilated, compared to 350 (49.6%) without dexamethasone. Ventilated patients with dexamethasone were more likely to have any pathogen detection than those without (p < 0.026; OR = 1.41; 95% CI 1.04-1.91). A significantly higher risk for the respiratory detection of Klebsiella spp. (p = 0.016; OR = 1.68 95% CI 1.10-2.57) and for Enterobacterales (p = 0.008; OR = 1.57; 95% CI 1.12-2.19) was found for the dexamethasone cohort. Invasive ventilation was an independent risk factor for in-hospital mortality (p < 0.01; OR = 6.39; 95% CI 4.71-8.66). This risk increased significantly in patients aged 80 years or older by 3.3-fold (p < 0.01; OR = 3.3; 95% CI 2.02-5.37) when receiving dexamethasone.

Conclusion: Our results show that the decision to treat COVID-19 patients with dexamethasone should be a matter of careful consideration as it involves risks and bacterial shifts.

Keywords: COVID-19 pandemic; SARS-CoV-2; bacteria; critical care.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work.

Figures

Figure 1
Figure 1
Pathogen detection in the invasive ventilation group. BS, blood samples; RS, respiratory samples; bold indicates statistically significant.
See this image and copyright information in PMC

References

    1. Wang Z., Wang N., Yang L., Song X.Q. Bioactive natural products in COVID-19 therapy. Front. Pharmacol. 2022;13:926507. doi: 10.3389/fphar.2022.926507. - DOI - PMC - PubMed
    1. Yang L., Wang Z. Natural products, alone or in combination with FDA-approved drugs, to treat COVID-19 and lung cancer. Biomedicines. 2021;9:689. doi: 10.3390/biomedicines9060689. - DOI - PMC - PubMed
    1. Pribanić Matešić M., Kučan Brlić P., Lenac Roviš T., Mačak Šafranko Ž., Chaouat A.E., Miklić K., Malić S., Ivanković N., Schubert M., Bertoglio F. Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins. Viruses. 2022;14:443. doi: 10.3390/v14020443. - DOI - PMC - PubMed
    1. Arduini A., Laprise F., Liang C. SARS-CoV-2 ORF8: A Rapidly Evolving Immune and Viral Modulator in COVID-19. Viruses. 2023;15:871. doi: 10.3390/v15040871. - DOI - PMC - PubMed
    1. Cascella M., Rajnik M., Aleem A., Dulebohn S.C., Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19) [(accessed on 20 April 2023)];Statpearls. 2022 Available online: https://www.statpearls.com/ArticleLibrary/viewarticle/52171. - PubMed

Publication types